Characterization and humanization of a monoclonal antibody that neutralizes human leukocyte interferon: A candidate therapeutic for IDDM and SLE

Cytokine

Volumn 15, Issue 5, 2001, Pages 250-260

  Chuntharapai, Anan ^a   Lai, Jadine ^a   Huang, Xiaojian ^a   Gibbs, Verna ^a   Kim, K Jin ^a   Presta, Leonard G ^a   Stewart, Timothy A ^a  

^a GENENTECH INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON ANTIBODY; IMMUNOGLOBULIN LIGHT CHAIN; INTERFERON ANTIBODY; MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG;

ANIMAL MODEL; ARTICLE; BINDING AFFINITY; BINDING KINETICS; CELL STIMULATION; CONTROLLED STUDY; CROHN DISEASE; ELECTROPHORETIC MOBILITY; ENZYME LINKED IMMUNOSORBENT ASSAY; IMMUNOPHARMACOLOGY; INSULIN DEPENDENT DIABETES MELLITUS; LEUKOCYTE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PSORIASIS; RETROSPECTIVE STUDY; SEQUENCE ANALYSIS; SYSTEMIC LUPUS ERYTHEMATOSUS;

MURINAE;

EID: 0035823645     PISSN: 10434666     EISSN: None     Source Type: Journal    
DOI: 10.1006/cyto.2001.0934     Document Type: Article

References (79)

1. Humanized antibodies as potential therapeutic drugs
2. Engineering antibodies for the clinic
3. Immuno-reactive alpha-interferon in insulin-secreting beta cells in type 1 diabetes mellitus
4. Interferon expression in the pancreases of patients with type I diabetes
5. Pancreas in recent onset insulin-dependent diabetes mellitus. Changes in HLA, adhesion molecules and autoantigens, restricted T cell receptor V beta usage, and cytokine profile
6. Multiple interferons in the circulation of patients with systemic lupus erythematosus and vasculitis
7. Immune interferon in the circulation of patients with autoimmune disease
8. Serum alpha interferon and lymphocyte inclusions in systemic lupus erythematosus
9. Systemic lupus erythematosus: Presence in human serum of an unusual acid-labile leukocyte interferon
10. Serological markers of disease activity in systemic lupus erythematosus (Review, 95 refs)
11. Patients with systemic lupus erythematosus (SLE) have a circulating inducer of interferon-alpha (IFN-alpha) production acting on leucocytes resembling immature dendritic cells
12. A survey of adverse events in 11,241 patients with chronic viral hepatitis treated with alfa interferon
13. Occurrence of IDDM during interferon therapy for chronic viral hepatitis
14. Induction of insulin antibodies and insulin allergy under alpha-interferon treatment of renal cell carcinoma in a patient with insulin-treated diabetes mellitus - A case report
15. Onset of insulin-dependent diabetes mellitus after interferon-alfa therapy for hairy cell leukaemia
16. Development of type 1 diabetes mellitus during interferon alfa therapy for chronic HCV hepatitis
17. Exacerbation of symptoms of autoimmune disease in patients receiving alpha-interferon therapy
18. Side effects of alpha interferon in chronic hepatitis C
19. The side effects associated with the interferon-alpha therapy of chronic viral hepatitis
20. Autoimmunity after alpha-interferon therapy for malignant carcinoid tumors
21. Systemic lupus erythematosus in a child receiving long-term interferon therapy
22. Interferon-alpha-induced human lupus inclusions and p36 protein in cancer and AIDS
23. Lupus-like autoimmune disease induced by interferon therapy for myeloproliferative disorders
24. Control of islet intercellular adhesion molecule-1 expression by interferon-alpha and hypoxia
25. Islet expression of interferon-alpha precedes diabetes in both the BB rat and streptozotocin-treated mice
26. Induction of type I diabetes by interferon-alpha in transgenic mice
27. Nomenclature of the human interferon genes
28. The type I interferon receptor: Structure, function, and evolution of a family business
29. The interferon receptors
30. Interferon-alpha in lupus psychosis
31. Serum levels of interferons in patients with systemic lupus erythematosus
32. Presence of interferon and anti-interferon in patients with systemic lupus erythematosus
33. Association of interferon gamma, tumor necrosis factor alpha and interleukin 6 serum levels with systemic lupus erythematosus activity
34. Cytokine concentration in serum of lupus erythematosus patients: The effect on acute phase response
35. Antigenic characterization of recombinant, lymphoblastoid, and leukocyte IFN-alpha by monoclonal antibodies
36. Production and characterization of four monoclonal antibodies specific for human interferon-alpha-1 and -alpha-2
37. Production of hybridomas secreting monoclonal antibodies to the human leukocyte interferons
38. A comparison of the neutralizing properties of monoclonal and polyclonal antibodies to human interferon alpha
39. Initiation of humoral and cellular immune responses in patients with refractory Hodgkin's disease by treatment with an anti-CD16/CD30 bispecific antibody
40. Human anti-mouse antibody response induced by anti-CD4 monoclonal antibody therapy in patients with rheumatoid arthritis
41. Pharmacology and safety assessment of humanized monoclonal antibodies for therapeutic use
42. Cytoplasmic activation of ISGF3, the positive regulator of interferon-alpha-stimulated transcription, reconstituted in vitro
43. Humanization of an anti-lymphocyte function-associated antigen (LFA)-1 monoclonal antibody and reengineering of the humanized antibody for binding to rhesus LFA-1
44. Humanization of an anti-p185HER2 antibody for human cancer therapy
45. Humanization of an antibody directed against IgE
46. X-ray structures of fragments from binding and nonbinding versions of a humanized anti-CD18 antibody: Structural indications of the key role of VH residues 59 to 65
47. Conformations of immunoglobulin hypervariable regions
48. Framework residues 71 and 93 of the chimeric B72.3 antibody are major determinants of the conformation of heavy-chain hypervariable loops
49. Framework residue 71 is a major determinant of the position and conformation of the second hypervariable region in the VH domains of immunoglobulins
50. The type I interferon system is locally activated in psoriatic lesions
51. Interferon expression in Crohn's disease patients: Increased interferon-gamma and -alpha mRNA in the intestinal lamina propria mononuclear cells
52. Human recombinant interferon alpha-2C enhances the expression of class II HLA antigens on hairy cells
53. Modulation of expression of MHC antigens in the kidneys of mice by murine interferon-alpha/beta
54. Alpha-interferon induces enhanced expression of HLA-ABC antigens and beta-2-microglobulin in vivo and in vitro in various subsets of human lymphoid cells
55. Differential expression and regulation of MHC products in the endocrine and exocrine cells of the human pancreas
56. Antigen presentation by human monocytes: Effects of modifying major histocompatibility complex class II antigen expression and interleukin 1 production by using recombinant interferons and corticosteroids
57. IFN-alpha induces autoimmune T cells through the induction of intracellular adhesion molecule-1 and B7.2
58. Type I interferons keep activated T cells alive
59. Type I interferon-mediated stimulation of T cells by CpG DNA
60. Role of type I interferons in T cell activation induced by CpG DNA
61. Induction of bystander T cell proliferation by viruses and type I interferon in vivo
62. Anti-double-stranded DNA antibodies and immunostimulatory plasmid DNA in combination mimic the endogenous IFN-alpha inducer in systemic lupus erythematosus
63. Functional role of type I and type II interferons in antiviral defense
64. Phase II study of weekly intravenous trastuzumab (Herceptin) in patients with HER2/neu-overexpressing metastatic breast cancer
65. Supersaturating infusional humanized anti-CD33 monoclonal antibody HUM195 in myelogenous leukemia
66. Phase I evaluation of humanized OKT3: Toxicity and immunomodulatory effects of hOKT3gamma4
67. Fusion of mouse myeloma and spleen cells
68. A practical cytopathic effect/dye-uptake interferon assay for routine use in the clinical laboratory
69. Metal binding properties of a monoclonal antibody directed toward metal-chelate complexes
70. Structure-function study of the extracellular domain of the human IFN-alpha receptor (hIFNAR1) using blocking monoclonal antibodies: The role of domains 1 and 2
71. Rapid and efficient site-specific mutagenesis without phenotypic selection
72. Construction and characterization of an active factor VIII variant lacking the central one-third of the molecule
73. Characteristics of a human cell line transformed by DNA from human adenovirus type 5
74. Binding of auto-reactive mouse anti-type II collagen antibodies derived from the primary and the secondary immune response investigated with the biosensor technique
75. The human intracellular Mx-homologous protein is specifically induced by type I interferons
76. Quantitation of interferon-induced Mx protein in whole blood lysates by an immunochemiluminescent assay: Elimination of protease activity of cell lysates in toto
77. A novel bioassay for the determination of neutralizing antibodies to IFN-beta1b
78. Real time quantitative PCR